IDIS Pharma
http://www.idispharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From IDIS Pharma
Zydus To Slice Into Shrinking Revlimid Pie ‘In Near Term’ As Asacol Revenues Erode
Zydus is set to join Natco in chipping away at BMS’ blockbuster Revlimid with its generic version, probably from Q2 while Aurobindo expects to launch by FY24. Revenues from this drug are expected to offset erosion of generic Asacol revenues even as Zydus expects volume growth and new launches to help grow its US business.
Zydus To Slice Into Shrinking Revlimid Pie ‘In Near Term’ As Asacol Revenues Erode
Zydus is set to join Natco in chipping away at BMS’ blockbuster Revlimid with its generic version, probably from Q2 while Aurobindo expects to launch by FY24. Revenues from this drug are expected to offset erosion of gAsacol revenues even as Zydus expects volume growth and new launches to help grow its US business
FDA Announces Class I Recall On Arrow International Cardiac Catheter Device
The US FDA has announced a high-risk class I recall on a cardiac catheter from Teleflex Inc. subsidiary Arrow International due to the risk of tip damage during use.
Tech Transfer Roundup: Athenex, PDS Align With National Cancer Institute On Oncology R&D
Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.
Company Information
- Other Names / Subsidiaries
-
- Idis Group Holdings Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice